Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6417124 | 1.00 | LMNA (0.50) | LMNAMEN1KMT2AHTTPTPN1 | |
| SCHEMBL17865779 | 0.89 | LMNA (0.58) | LMNAHTTMAOBAOC3 | |
| SCHEMBL24554348 | 0.84 | MEN1 (0.47) | MEN1KMT2AHTTPTPN1CES2 | |
| SCHEMBL1233194 | 0.84 | MEN1 (0.47) | MEN1KMT2AHTTPTPN1CES2 | |
| SCHEMBL2522600 | 0.83 | LMNA (0.53) | LMNAKMT2AHTTMAOBAOC3 | |
| SCHEMBL1742088 | 0.82 | EGLN1 (0.50) | MEN1KMT2APTPN1CES2CES1 | |
| SCHEMBL14009645 | 0.82 | MAOB (0.65) | LMNAMEN1KMT2AHTTMAOB | |
| SCHEMBL7753604 | 0.82 | TRPV1 (0.59) | LMNAHTTPTPN1CES2CES1 | |
| SCHEMBL3757683 | 0.81 | NPC1 (0.52) | MEN1KMT2APTPN1NPC1RAB9A | |
| SCHEMBL12206267 | 0.81 | KCNN4 (0.48) | MEN1KMT2APTPN1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333577-A1 | QUINOLINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE IN DIAGNOSIS | Westfälische Wilhelms-Universität Münster (DE) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333577-A1 | QUINOLINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE IN DIAGNOSIS | S100A9, S100A4, S100A10 | LMNA 861/4885MEN1 3766/4885KMT2A 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.